Phase 1/2 study of S-288310 in patients with bladder cancer

Trial Profile

Phase 1/2 study of S-288310 in patients with bladder cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs S 288310 (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 20 Dec 2016 Primary endpoint of immunological assessment (in vitro cytotoxic T lymphocytes response) has not been met, according to result published in the Annals of Oncology.
    • 20 Dec 2016 Results published in the Annals of Oncology
    • 01 Oct 2013 Interim results presented at the 2013 European Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top